Patients not treated with adjuvant TACE, compared with those treated with adjuvant TACE, had a higher proportion of HBV-DNA > 2000 IU/mL (28.0% vs. 17.1%, P = .013), prothrombin time (PT) > 13 s (20.4% vs. 9.95%, P = .005), platelets (PLT) ≤100 * 109/mL (26.3% vs. 11.8%, P < .001) and cirrhosis (77.4% vs. 66.8%). The gene discussed is F2; the disease is Cirrhosis.